Regeneron Pharmaceuticals (BMV:REGN *) - Aandelenkoers, Nieuws & Analyse

REGN * Overzicht aandelen

Regeneron Pharmaceuticals, Inc. ontdekt, bedenkt, ontwikkelt, produceert en verkoopt wereldwijd geneesmiddelen voor de behandeling van verschillende ziekten. Meer informatie

REGN * fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 55.9% onder onze schatting van de reële waarde

De winst groeide het afgelopen jaar met 16.6%

Analisten zijn het erover eens dat de aandelenkoers met 44.8% zal stijgen

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Regeneron Pharmaceuticals, Inc. Concurrenten

CSL

ASX:CSL

AU$131.4b

Amgen

NasdaqGS:AMGN

US$150.5b

Biogen

NasdaqGS:BIIB

US$22.6b

AbbVie

NYSE:ABBV

US$294.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Regeneron Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$14,937.40
52 Week Hoogtepunt	US$23,707.11
52 Week Laag	US$13,696.61
Bèta	0.14
11 maand verandering	-24.17%
3 maanden verandering	-35.08%
1 Jaar Verandering	8.23%
33 jaar verandering	9.15%
5 jaar verandering	105.68%
Verandering sinds IPO	64.58%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	REGN *	MX Biotechs	MX Markt
7D	-12.0%	0%	0%
1Y	8.2%	0%	0%

Rendement versus industrie: REGN * kwam overeen met de MX Biotechs industrie, die het afgelopen jaar een rendement opleverde van 8 %.

Rendement versus markt: REGN * overtrof de MX markt, die het afgelopen jaar een rendement opleverde van -3.7 %.

Prijsvolatiliteit

Is REGN *'s price volatile compared to industry and market?
REGN * volatility
REGN * Average Weekly Movement	6.7%
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: De aandelenkoers van REGN * is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van REGN * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1988	14,165	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. ontdekt, bedenkt, ontwikkelt, produceert en verkoopt wereldwijd geneesmiddelen voor de behandeling van verschillende ziekten. De producten van het bedrijf omvatten EYLEA-injectie voor de behandeling van leeftijdsgebonden maculadegeneratie en diabetisch macula-oedeem; bijziend choroïdale neovascularisatie; diabetische retinopathie; neovasculair glaucoom; en retinopathie van prematuriteit. Het levert ook Dupixent injectie voor de behandeling van atopische dermatitis en astma bij volwassenen en kinderen; Libtayo injectie voor de behandeling van metastatisch of lokaal gevorderd cutaan plaveiselcelcarcinoom; Praluent injectie voor heterozygote familiaire hypercholesterolemie of klinische atherosclerotische cardiovasculaire aandoeningen bij volwassenen; REGEN-COV voor covid-19; en Kevzara oplossing voor de behandeling van reumatoïde artritis bij volwassenen.

Regeneron Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Regeneron Pharmaceuticals zich tot de beurswaarde?
REGN * fundamentele statistieken
Marktkapitalisatie	Mex$1.61t
Inkomsten(TTM)	Mex$93.64b
Inkomsten(TTM)	Mex$278.56b

17.2x

Koers/Winstverhouding

5.8x

P/S-verhouding

Is REGN * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
REGN * resultatenrekening (TTM)
Inkomsten	US$13.85b
Kosten van inkomsten	US$6.82b
Brutowinst	US$7.03b
Overige uitgaven	US$2.37b
Inkomsten	US$4.65b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	43.26
Brutomarge	50.75%
Nettowinstmarge	33.61%
Schuld/Eigen Vermogen Verhouding	6.8%

Hoe presteerde REGN * op de lange termijn?

Bekijk historische prestaties en vergelijking

REGN * Overzicht aandelen

Beloningen

Risicoanalyse

Regeneron Pharmaceuticals, Inc. Concurrenten

ASX:CSL

AU$131.4b

NasdaqGS:AMGN

US$150.5b

NasdaqGS:BIIB

US$22.6b

NYSE:ABBV

US$294.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Senior VP of Finance & CFO recently sold Mex$124m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Insider recently sold Mex$108m worth of stock

Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023)

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

New minor risk - Shareholder dilution

First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023)

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Executive VP recently sold Mex$17m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Insider recently sold Mex$168m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Regeneron Pharmaceuticals, Inc. Samenvatting

17.2x

5.8x

Inkomsten en omzet